Fig. 8
From: Targeting the USP7-CDK1 axis suppresses estrogen receptor-positive breast cancer progression
Dual inhibition of USP7 and CDK1 synergistically causes apoptosis in ERPBC cells. (A) IC50 value of CDK inhibitor (Ro-3306) for MCF7 (left) and T47D (right) cells at 48 and 72Â h. (B) Viability of MCF7 (left) and T47D (right) cells following combined GNE-6776 and Ro-3306 treatment assessed via MTT assay. (C) Apoptosis levels of MCF7 (upper) and T47D (lower) cells following combined GNE-6776 and Ro-3306 treatment assessed via Annexin V-based flow cytometry analysis. (D) Quantitative analysis for apoptotic levels of MCF7 (left) and T47D (right) cells with GNE-6776 and Ro-3306 treatment. (E) Depolarization of mitochondria membrane potential (MMP) following combined treatment of MCF7 (upper) and T47D (lower) cells with GNE-6776 and Ro-3306 assessed via flow cytometry analysis. (F) Quantitative analysis of depolarized levels of MMP in combined GNE-6776- and Ro-3306-treated MCF7 (left) and T47D (right) cells